Summary
Urethane (ethyl carbamate) is used alone or in combination with other drugs to produce anaesthesia in laboratory animals. Although originally studied as a potential phytocide, urethane demonstrated antineoplastic properties when administered to rats with the Walker rat carcinoma 256. Subsequent trials in humans led to its use as a chemotherapeutic agent for various leukaemias. Mice develop pulmonary adenomas earlier in life and at a higher incidence following urethane administration. Urethane's carcinogenic influence is greater in neonatal mice; it also has a transplacental influence in mice. In rats, urethane increases the incidence of pulmonary adenomas, Zymbal Gland tumours, and a variety of other neoplasms. Urethane is absorbed sufficiently from the skin of laboratory animals to produce a transient narcosis. The carcinogenic effect appears to be due to an undefined oncogenic intermediate formed in the blood. Considering the properties urethane demonstrates in animals, the safety of its use by laboratory personnel is in question. However, if appropriate guidelines are followed, urethane should continue to be a useful anaesthetic agent for laboratory animals.
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Urethane (ethyl carbamate) has long been considered a desirable compound for providing anaesthesia during physiological experiments. Received 3 February 1987; accepted 6 January 1988 However, in addition to the notable anaesthetic properties, several adverse traits have been recognized when urethane is administered to animals and humans. These traits have been known for many years, yet they are relatively unappreciated by many investigators. Therefore, the purpose of this paper is to review the development, use, and adverse properties of urethane. Special consideration will be directed towards reviewing data that assists in developing guidelines for the safe handling of urethane. For a more comprehensive review of urethane, the readers are referred to the excellent review articles by Mirvish (1968) and The World Health Organization (1974) .
History
In 1939, a study was conducted on wheat seedlings using a variety of carbamate analogues, in an attempt to identify plant growthpromotants and growth-inhibitors (Templeton & Sexton, 1945) . The data obtained from the study suggested that, depending on the level of exposure to ethyl pheny1carbamate (one of many ethyl carbamate analogues), wheat seedlings would develop one or more of the following abnormalities: bulbous hypertrophy of the seed leaf or root tip; stunted growth; arrested growth at the seed-leaf stage; thick bulbous stem formation; or plant death (Templeton & Sexton, 1945; Haddow & Sexton, 1946) . Other investigators confirmed these findings, and observed similar results in winter rye, barley and oat plants (Haddow & Sexton, 1946) . These investigators also noted that by varying the level of plant exposure to ethyl phenylcarbamate, they could inhibit weed growth without affecting the growth of desirable plants (Haddow & Sexton, 1946) .
Some investigators, believing that the carbamates would contain several important and inexpensive herbicides, evaluated approximately 50 related aryl carbamates and thiocarbamates for their influence on plant growth and development (Templeton & Sexton, 1945) . At the conclusion of this project, urethane proved to be one of the few analogues that failed to influence plant growth or development (Templeton & Sexton, 1945; Haddow & Sexton, 1946) . This was a peculiar finding, considering that literature was available on the ability of urethane to suppress bacterial, protozoal, sea urchin egg, and plant tissue growth in vitro (Haddow & Sexton, 1946) .
Both ethyl phenylcarbamate and isopropyl phenylcarbamate, two of urethane's analogs, were known to retard the growth of the Walker rat carcinoma 256. Therefore, urethane was further investigated as a potential agent against this tumour (Haddow & Sexton, 1946) . Interestingly, the antineoplastic activity of urethane, a compound which previously demonstrated no observable influence on plant growth, was greater than either of the two phenylcarbamates previously mentioned (Haddow & Sexton, 1946) . The action of urethane against the Walker rat carcinoma was accompanied by profound modifications in the histological structure of the tumour which were suggestive of remission (Haddow & Sexton, 1946) . Intrigued with the thought that a compound as readily available and structurally simple as urethane would be of antineoplastic value, urethane was quickly introduced into the clinical setting for evaluation in human cancer patients (Haddow & Sexton, 1946; Paterson et al., 1946) .
Shortly thereafter, urethane was administered to several human patients with advanced, inoperable, and otherwise intractable mammary carcinomas (Haddow & Sexton, 1946; Paterson et al., 1946) . Unfortunately, the results of the initial clinical trials were negative (Haddow & Sexton, 1946) . Nevertheless, the investigators Field & Lang elected to pursue an extended course of therapy with these patients, a decision which provided to be fortuitous: chronic urethane therapy resulted in leukopenia (Haddow & Sexton, 1946; Paterson et al., 1946) . Clinical trials on urethane were quickly extended to include individuals with leukaemia and other lymphadenopathies, and the results were encouraging (Haddow & Sexton, 1946; Paterson et al., 1946) .
Urethane has since been used in humans (total dose of 2-6 g/day) as a chemotherapeutic agent against chronic granulocytic leukaemia, multiple myeloma (plasma-cell myeloma) and to a lesser extent, chronic lymphocytic leukaemia (Haddow & Sexton, 1946; Di Palma, 1965) . Urethane has also been used in humans as a hypnotic agent, as an adjunct to sulphonamide therapy, as a component of a sclerosing agent (with quinine) for varicose veins, and as a topical bactericide (WHO, 1974) . Currently there are several drugs that demonstrate higher specificity than urethane for treating these diseases in humans.
In humans, chronic urethane therapy results in leukopenia, sedation, nausea, vomiting, and hepatic necrosis (Hirschbaeck et al., 1948; Hoover, 1970) . Additional reports indicate that urethane may also cause irreversible aplastic anaemia (Bottner, 1949) , lymph node fibrosis, and fatal pneumonia secondary to agranulocytosis (Letterer, 1949) .
The primary use of urethane today is as an anaesthetic agent for laboratory animals (Hoover, 1970; Jones et al., 1977) .
Chemical and physical properties
Urethane, the ethyl ester of carbamic acid, (NH 2 COOC 2 H 5 ) is a colourless, almost odourless, columnar crystal or white granular powder (Hirschbaeck et al., 1948; WHO, 1974) . The similarity of carbamic acid esters to urea resulted in the classification of these compounds as urethanes (Hirschbaeck et al., 1948) . Urethane is readily soluble in water, alcohol, and lipids (Mirvish, 1968; Jones et al., 1977) . At 25°C, 1g of urethane dissolves in O· 5 g of water, at room temperature urethane volatilizes, and at 103°C urethane sublimes (WHO, 1974) .
Anaesthesia
Urethane has been used for many years to produce hypnosis and narcosis in mammals, fish, and amphibians (Rossoff, 1974; Green, 1982) . Urethane is specifically indicated for procedures in which the investigator requires anaesthesia that lasts for hours with minor alterations in the patients physiologic parameters. At anaesthetic dosages (1-1' 2 g/kg body weight for rats) urethane has a wide margin of safety and causes minimal changes in blood pressure, aortic blood flow, and blood-gas values (Folle & Levesque, 1976; Buelke-Sam et al., 1978; DeWildt et al., 1983) .
When used in combination with alpha chloralose, urethane increases the solubility of chloralose, augments the activity of chloralose, and provides the necessary analgesia for surgical anaesthesia (Green, 1982) . Urethane will also suppress excess muscle activity, exaggerated spinal reflex activity, and central nervous system stimulation commonly associated with chloralose anaesthesia (Hughes et al., 1982) . In addition, the stable respiratory patterns associated with chloralose anaesthesia are retained (Hughes et al., 1982) . This combination is capable of providing extended periods of basal narcosis in non-recovery experiments (Folle & Levesque, 1976) .
When urethane is administered intraperitoneally (IP) in the rat, peritoneal fluid accumulates, the rat fails to exhibit a renal response to NaCI and water loading, and a pronounced hyperosmolarity of body fluids develops (Severs et al., 1981) . Other investigators have found that urethane increases plasma renin activity and aldosterone concentrations, and reduces pressor responses to angiotensin II (Pettinger et al., 1975; Sonkodi & Nafradi, 1979) . These findings suggest that urethane is not the anaesthetic of choice in studies involving the renninangiotensin-aldosterone system.
Mutagenic and anti-mitotic evidence
When urethane is administered to Drosophila, mutagenic properties similar to those created with X-ray radiation have been observed 257 (Auerbach, 1967) . Chromosomal breakage and recombination will occur and gene mutations develop without evidence of chromosomal breakage (Auerbach, 1967) .
At a dosage of 1g/kg IP, (which is the normal anaesthetic dose in most species), urethane will arrest cell division in the crypt of liberkuhn cells in mice (Bastrupt-Madien, 1949) . Urethane is known to be cytotoxic to dividing cells, thereby decreasing mitotic activity. Studies involving chick-embryo heart-fibroblast cell cultures have shown that chromosomal division is arrested at metaphase and the chromosomes are unable to separate (Bastrup-Madien, 1949) . This finding may partially explain urethanes antineoplastic properties.
Absorption and distribution Following IP injection of radioactively labelled urethane into mice (C14), no specific tissue localization occurs; urethane distributes to all tissues in the body (Bryan et al., 1957) . In vivo, urethane is metabolized to ammonia, carbon dioxide, and ethyl alcohol (Bryan et al., 1957; Boyland & Nery, 1965) . Approximately 90070of the radioactivity is detected in the expired carbon dioxide and 5-1 0% is detected in the urine (Bryan et al., 1957) . In mice, when urethane is applied directly to the skin, a sufficient amount is absorbed to induce a transient narcosis (Cowen, 1950b; Salaman & Roe, 1953) . Urethane is also well absorbed when administered by either the oral or subcutaneous route (Henshaw & Meyer, 1945) .
Carcinogenesis in mice
Mice are more sensitive to the carcinogenic effects of urethane as neonates, developing tumours at a higher incidence than older mice (Rogers, 1951) . Studies have shown that newborn mice eliminate urethane at one-tenth the rate as adult mice (Mirvish, 1968) . The time required to catabolize 50070of urethane in the newborn mice decreased steadily during the first 20 days of life, whereas the rate of elimination increased during the same period. In one study, a dose of O' 5 mg/g body weight was completely eliminated in adult mice within 8 h, whereas newborn mice required 72 h to eliminate the same dose (Mirvish, 1968) . The slower metabolism of urethane in newborn mice appears to explain, in part, their greater sensitivity to urethane carcinogenesis.
When urethane is administered to mice at anaesthetic (1 mg/g body weight) or subanaesthetic doses, several carcinogenic changs have been observed (Henshaw & Meyer, 1944; Cowen, 1947; Klien, 1954; Boyland & Nery, 1965) . Mice that spontaneously develop pulmonary adenomas will do so at a higher incidence than normal, and the tumours will occur earlier in life following a single injection of urethane (Cowen, 1947) . For example, greater than 75!1Jo of strain A mice normally develop pulmonary adenomas at 18 months of age. Following urethane anaesthesia (1 mg/g body weight), these mice will have greater than 75ftJo incidence of pulmonary adenomas at 6 Y2 months of age. In a separate study, a single IP injection of urethane given to 6-8 week old mice was sufficient to induce formation of grossly detectable pulmonary adenomas 4Yz months postinjection (Henshaw & Meyer, 1944) . A single IP injection in the C3H strain of mice increased the incidence of pulmonary adenomas from 50/0to greater than 75% (Nettles hip et al., 1943; Henshaw & Meyer, 1944) . Other investigators have found that the number of lung tumours found in mice increases linearly with the number of dosages of urethane administered (Henshaw & Meyer, 1944; Kay & Trainin, 1966) .
The lifetime incidence of pulmonary adenomas in Swiss mice is less than 1.0%, however, studies have shown that a single subcutaneous injection of urethane in 24 hold Swiss mice resulted in a 21' 6% incidence of malignant lymphomas at 6 months of age (Fiore-Donati et al. 1961) . In C57BL mice, a single subcutaneous injection of urethane at 24 h of age, followed by one subcutaneous injection a week for 7 weeks resulted in 100% of the mice having thymic lymphomas by 17 weeks of age (Doell & Carnes, 1962) . Normally, only 3% of these mice present with thymic lymphomas at Field & Lang 15 months of age (Doell & Carnes, 1962; Boyland & Nery, 1965) .
Application of urethane directly to the skin of mice does not appear to induce skin tumours, yet there is histological evidence that preneoplastic changes are initiated (Salam an & Roe, 1953). Furthermore, skin tumours will form if a promoting agent is applied to the skin after urethane has initiated these preneoplastic changes (Salaman & Roe, 1953; Boyland & Nery, 1965) . Application of urethane to the skin will also result in an increased incidence of pulmonary adenomas, again reflecting the ability of urethane to be absorbed transdermally (Cowen, 1950b) .
In mice, urethane also augments leukaemogenesis caused by X-rays, oestrogens, and methylchloanthrene (Boyland & Nery, 1965 ).
Genetics of lung tumour development in mice
The ability of urethane to produce lung tumours in mice follows a specific strain order which parallels the order of spontaneous lung tumour development in these same strains of mice (Cowen, 1950a; Shapiro & Kirschbaum, 1951) . According to Shapiro and Kirschbaum (1951) , the order of susceptibility is A> Swiss> CBA > DBA, whereas Cowen (1950a) found the order to be A> CBA > C57BL.
Additional work was conducted to further define this strain susceptibility to lung tumour development. Cowen (1950a) found that the FI offspring of an A x C57BL mating developed less tumours than strain A mice, but considerably more tumours than C57BL mice. When F1 mice were backcrossed to the C57BL parents, the offspring segregated into two approximately equal sized groups: one group developed tumours at a rate similar to the A x C57BL F1 mice, and the other group developed tumours at the same rate as C57BL mice. These results suggest that a single dominant gene is responsible for the susceptibility of mice to tumour formation.
Studies by Shapiro and Kirschbaum (1951) found that when Bagg albino mice (susceptible to urethane induced lung tumours) were crossed with DBA mice (resistant to urethane induced lung tumours), the Fl was also susceptible to urethane induced lung tumours. Lung was then transplanted from Bagg X Bagg Fl mice and DBA X DBA Fl mice into the left and right ear of Bagg X DBA Fl mice respectively. Urethane treatment of the Bagg x DBA PI recipient resulted in 12/17 Bagg transplants developing tumours, whereas only 1/17 DBA transplants developed tumours. Since the recipient of the transplants was identical for both parent strains, the results suggest that the carcinogenic potential of urethane on lung tissue is an intrinsic property of that tissue. The authors further suggested that urethane may simply potentiate the intrinsic potential of a tissue to spontaneously develop tumours.
Transplacental influences in mice Experimental results from pregnant Strain A mice injected with urethane were startling. Following IP injection of pregnant mice with urethane, the fetuses were removed by caesarean section at various postinjection intervals. Mice exposed to urethane for as few as 5 min during fetation showed a marked increase in pulmonary adenoma formation at 6 months of age when compared to mice that were not exposed to urethane during fetation (Klien, 1954) . In a similar experiment C57BL x C3H Fl mice exposed to urethane late in gestation had an increased incidence of hepatomas, ovarian tumours, and harderian gland cystadenomas following intrauterine exposure to urethane (Vesselinovitch et al., 1971) . Rogers (1955) conducted a study in which fetal lung tissue was transplanted subcutaneously into recipient BALB/c or Strain A mice following one of three protocols: the fetal lung was transplanted without exposure to urethane (control); the fetal lung was transplanted following direct exposure to urethane; or the fetal lung was transplatned following direct exposure to the serum from urethane treated animals. The results of this study showed that direct exposure of the transplanted fetal lung tissue to urethane did not induce pulmonary 259 adenoma formation. In contrast, direct exposure of the transplanted fetal lung tissue to serum from urethane treated animals resulted in an increased incidence of pulmonary adenomas when compared to control animals. The data suggest that urethane does not act directly on the lung tissue, but that an oncogenic intermediate is responsible for tumour induction (Rogers, 1955) . In addition, this oncogenic intermediate is produced by rats, mice and rabbits (Rogers, 1955) , and the identity of the oncogenic intermediate is presently unknown (Mirvish, 1968) .
Work performed by Malmgreen and Sexton (1953) supporSs the conclusion that an oncogenic intermediate is responsible for pulmonary adenoma formation. Furthermore, Malmgreen and Sexton's (1953) results suggest that the oncogenic intermediate is capable of inducing tumour formation for approximately 24 h following urethane administration. The 24 h period of effect may be explained by the fact that more than 90070 of the urethane administered to the animal is metabolized and eliminated from the body within 24 h (Malmgreen & Sexton, 1953) .
Carcinogenesis in rats
At a dose of I g/kg IP, pulmonary adenomas can be induced in laboratory rats following urethane administration (Jaffe, 1947; Tannenbaum et al., 1962) . This is an interesting finding, since the rat lung has always shown remarkable resistance to other carcinogenic agents (Jaffe, 1947) . In fact, it is rare for the laboratory rat to develop pulmonary neoplasms under natural or experimental conditions (Riebl in & McCoy, 1965; Benirschke et al., 1978) Urethane also potentiates formation of Zymbal gland carcinomas, enhances formation of angiomas and sarcomas, induces malignant lymphomas and tumours of the kidney, and increases the formation of neurofibrosarcomas of the ear (Tannenbaum et al., 1962) . All of these results can be obtained following IP injection, or administration of urethane in the drinking water.
Bone marrow suppression Studies
have shown that mice are more susceptible to infections following urethane administration.
This appears to be related to a decrease in resistance to infections resulting from bone marrow suppression (Cowen, 1947; Cruz & Mousstache, 1948; Moeschlin & Bodner, 1951) . Urethane has been shown to cause a dose related bone marrow suppression in cats and dogs (Cruz & Mousstache, 1948; Moeschlin & Bodner, 1951) . In cats, a small dose (0' 5 g/kg/ day) inhibits maturation of granulocytes and thrombocytes, and at a large dose, 0·1 g/kg/day) results in depletion of all marrow cells (Moesch lin & Bodner, 1951) . Neutropenia, lymphocytopenia, thrombocytopenia, and anaemia develop in cats; thrombocytopenia, leucopenia, acute-onset anaemia, and intestinal haemorrhage have been observed in dogs (Cruz & Mousstache, 1948; Moeschlin & Bodner, 1951) . Thrombocytopenia purpura of the small intestine, skin, heart, lung, renal cortex, omentum, stomach and large intestine has also occurred in dogs (Cruz & Mousstache, 1948) . The effects on the bone marrOw are reversible, with the time period from suppression to recovery being related to the total dosage of urethane administered (Moeschlin & Bodner, 1951) .
Carcinogenic and immunosuppressive data in humans There are presently no case reports or epidemiological studies available on the carcinogenic potential of urethane in humans (WHO, 1974) . This may be related to the fact that urethane was used mainly as a chemotherapeutic agent in terminal cancer patients; long term follow-up data may not be available from such patients. However, urethane is a known animal carcinogen and should consequently be treated as a potential human carcinogen.
Urethane is a well established immunosuppressive agent in humans at a dosage of 2-6 g per day. There are reports of humans developing irreversible aplastic anaemia (Bottner, 1949) , lymph node fibrosis, and fatal pneumonia Field & Lang secondary to agranulocytosis (Letterer, 1949) following treatment with urethane. When the immunosuppressive findings are coupled with the knowledge that urethane is well absorbed across the skin, casual skin contact could obviously pose a serious health risk to humans.
Recommendations
Many industrial chemicals (e.g. xylene, formaldehyde, concentrated acids) encountered in the research laboratory are hazardous to laboratory personnel if handled with indiscretion. Nevertheless, these agents continue to be used safely by laboratory personnel. Similarly, many anaesthetic agents used in laboratory animal medicine (e.g. etorphine, car fentanyl) are hazardous if handled with indiscretion. In fact, many of these agents pose a more immediate risk to laboratory personnel than does urethane. Therefore, it seems plausible that if the anaesthetist is aware of the potential adverse traits of urethane, appropriate guidelines can be adopted to promote safe handling and use of this compound.
The following is an example of guidelines one might take to minimize the risk of exposure to urethane: 1. When handling urethane in the crystalline or powdered form, and when mixing urethane into aqueous solutions, always wear a face mask, protective eye-wear, and chemical resistant gloves. 2. In order to prevent inhaling the volatilized drug, mix urethane in a fume hood. Urethane should only be heated if mixing takes place in a fume hood. 3. Gloves should be worn if the investigator is to come in contact with blood or serum from an animal anaesthetized with urethane. 4. Open containers of urethane should never be permitted. Once mixed into an aqueous solution, urethane should then be transferred into a sealed bottle. This will prevent volatilization, spillage, and accidental contamination of the environment. 5. If accidental contact of the skin, eyes, or other mucous membranes occurs, the area of contact should be washed thoroughly with water. Repeated transdermal exposure could potentially result in bone marrow suppression. 6. Pregnant women should avoid working with urethane.
The antimitotic potential of this compound, and the chromosomal damage that occurs in certain test systems is an important warning of the potential hazards of this agent. 7. Urethane (as with all anaesthetics) should be selected following careful consideration of the type of anaesthesia required. Urethane is not an appropriate agent for every anaesthetic protocol and should be used very selectively. Restrict the use of urethane to those projects that require long periods of stable anaesthesia. 8. Due to the long term carcinogenic effects of urethane in laboratory animals, this compound should be limited to use in non-recovery procedures.
Conclusion
Urethane is considered by many to be the drug of choice for providing long periods of anaesthesia with minimal physiological changes. Urethane is carcinogenic and mutagenic in mice, and carcinogenic in rats when used at anaesthetic dosages. Urethane is well absorbed following application to the skin, shows multiple organ effects, suppresses the bone marrow, readily crosses the placenta, induces tumour formation in utero, and initiates preneoplastic changes in the skin. The hazards of urethane to laboratory personnel have been recognized by previous investigators, (Cowen, 1950b; Rossoff, 1974; Green, 1982) , some prohibiting its use in their facility (Green, 1982) . Prohibiting the use of urethane as an anaesthetic removes an important agent from the hands of many investigaors.
Many other laboratory chemicals present similar or more dangerous hazards to laboratory personnel than does urethane, thus it seems plausible that guidelines can also be instituted to promote the safe handling of urethane.
Rather than prohibiting the use of urethane, a more judicious decision would be to inform investigators of the hazards of urethane, institute specific guidelines for handling, administering and disposing of urethane, and limit the use of urethane to only those procedures in which urethane is specifically indicated.
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